drugset
drugset / Trial / NCT06530914

A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma

NCT06530914 ↗

Phase 2 Not yet recruiting 30 enrolled Lei Liu
RandomizedParallel-groupOpen-labelTreatment

Summary

A Randomized, Phase II Study of MRG003 in Combination With Pucotenlimab Injection ± Cisplatin in Patients With Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma. This proposed study will evaluate the efficacy and safety of preoperative administration of MRG003 in Combination With Pucotenlimab Injection ± Cisplatin in HNSCC who are eligible for resection.

Timeline

Start
2024-08-01
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Becotatug Vedotin Monoclonal antibody — Intravenous
Subject Cisplatin Other / unclassified — Intravenous
Subject Pucotenlimab Monoclonal antibody — Intravenous

Indications

head and neck squamous cell carcinoma